FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
pharmaphorum1y
Sanofi cuts price of Lantus insulin in US by 78%
Sanofi has followed in the footsteps of its rivals in the US insulin market with a 78% price cut for its most widely-used Lantus product starting next January. It will restrict out-of-pocket costs ...
Medscape16d
Use of Concentrated Insulin Human Regular (U-500) for Patients with Diabetes
U-500 regular insulin has been available in the ... U-500 has prandial and basal time–action profile characteristics. d Basal insulin (glargine, detemir, or isophane [NPH]) may be substituted ...
Kiplinger1y
GoodRx Is Offering $35 Insulin Coupons — And You Don't Need Insurance
GoodRx said in a statement that it is working with Sanofi to offer U.S. insulin patients a coupon for to a 30-day supply of Lantus ... lower price right at their regular pharmacy counter ...
Nature1mon
Basal-bolus insulin regimen is effective for hospitalized patients with type 2 diabetes
compared the efficacy and safety of a basal-bolus insulin regimen with that of sliding-scale regular insulin (SSI ... to receive a basal-bolus regimen of glargine and glulisine (n = 65) or ...
pharmaphorum10y
Insulin glargine biosimilar approved in Europe
The marketing authorisation for the Alliance's insulin glargine product is based upon a comprehensive clinical data programme, which showed it has similar efficacy and safety compared to Lantus in ...
Medscape2d
FDA Okays New Rapid-Acting Biosimilar Insulin for Diabetes
The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...